Evidence map›Paper›PMID 30867237›Full record

ArticleJournal of clinical microbiology2019

Adrien Szekely, Andrew M Borman, Elizabeth M Johnson

Abstract readComparative Study
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Microbiology and molecular biology reviews : MMBR · 2026
    Review
  5. Microbiology spectrum · 2026
    Article
  6. UnderstandingJournal of medical microbiology · 2026
    Review
  7. Reaffirming the importance of nomenclature stability forJournal of clinical microbiology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Diagnostic Approaches forMicroorganisms · 2025
    Review
  12. Article
  13. Article
  14. The multidrug-resistantCurrent research in microbial sciences · 2025
    Review
  15. Emergence of multidrug-resistantFrontiers in microbiology · 2025
    Article
  16. Exploration of novel mechanisms of azole resistance inAntimicrobial agents and chemotherapy · 2024
    Article
  17. Emerging microbes & infections · 2024
    Article
  18. First report ofEmerging microbes & infections · 2024
    Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Adrien SzekelyUK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, United Kingdom.
Andrew M BormanUK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, United Kingdom Andy.Borman@nbt.nhs.uk.
Elizabeth M JohnsonUK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntifungal AgentsAsiaCandidaCommunicable Diseases, EmergingCycloheximideHumansLarvaMicrobial Sensitivity TestsMothsPhenotypeSouth AfricaUnited KingdomVirulenceAntifungal AgentsCycloheximideantifungal susceptibility testingCandida aurisclonal lineagesemerging pathogenpathogenic yeastsphenotypic characteristicsUnited Kingdom

Identifiers

PMID30867237
PMCPMC6498034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.